NCT02704741Unknown不适用
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 61
- 试验地点
- 7
- 主要终点
- Change from Baseline in Vulvovaginal Symptom Questionnaire
研究概览
简要总结
The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.
Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).
Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic.
详细描述
This study is a Prospective clinical study to demonstrate the CO2RE laser device for safety and efficacy for Vaginal Atrophy.
Up to a total of 60 healthy candidates, seeking vaginal treatment from the participating investigator will be enrolled at a participating study site. Subjects will receive three (3) CO2RE treatments.
Each subject will be followed for additional 5 post treatment visits (FU visits) that will be conducted at:
- One week post first treatment - 1wk FU ± 2 days (Safety).
- 1 month post last treatment - 1m FU ± 2 weeks (efficacy & Safety).
- 3 months post last treatment - 3m FU ± 2 weeks (efficacy & Safety).
- 6 months post last treatment - 6m FU ± 2 weeks (efficacy & Safety).
- 12 months post last treatment - 12m FU ± 2 weeks (efficacy & Safety).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subjects seeking treatment of Vaginal Atrophy in the vagina area (External - vestibule and introitus; Internal - Vaginal canal)
- •Healthy female subjects age greater than or equal to 35 years of age who are post menopausal for at least one year, for any reason whether surgical , chemical or natural.
- •Absence of menstruation for at least 12 months
- •Not responding to or satisfied with previous local estrogen therapy
- •Desire to maintain sexual activity
- •Informed consent process completed and subject signed consent
- •Willing to receive the proposed CO2RE treatment and follow-up protocol
- •Post-menopausal or surgically sterilized.
- •Normal cell cytology (PAP smear)
- •Negative urinalysis and a normal vaginal canal (no evidence of dysplasia and occult or active infection)
- •The external vaginal area (vestibule and introitus) free of injuries and bleeding
- •Subject experienced sexual activity at least once a month
排除标准
- •Subject had surgery or any other procedure for Vaginal Tightening in the last 12 months
- •Use of hormone replacement therapy, either systemic or local within the last 6 months prior to study
- •Lubricants or any localized preparation in the 30 days prior to enrollment
- •Patient with history of herpes.
- •Acute or recurrent urinary tract infection (UTI) or genital infection (e.g. herpes, candida)
- •Active malignancy or history of malignancy in the past 5 years
- •Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
- •Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the Physician would interfere with the treatment, or healing process)
- •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion)
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
- •Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen
- •History of significant lymphatic drainage problems
- •History of cancer which required lymph node biopsy or dissection
- •Suffering from significant conditions in the treated areas or inflammatory conditions, including, but not limited to, open lacerations or abrasions of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
- •History of keloid scarring, abnormal wound healing and / or prone to bruising
- •History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders
- •Use of isotretinoin (Accutane®) within 6 months of treatment or during the study
- •Subject on systemic corticosteroid therapy 6 months prior to and throughout the course of the study
- •Dysplastic nevi in the area to be treated
- •Participation in a study of another device or drug within 6 month prior to enrollment or during this study, if treatments of vagina were involved
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
- •Prolapse staged >_ II, according to the pelvic organ prolapse quantification (ICS-POP-Q) system
- •Previously undergone pelvic reconstructive surgery
结局指标
主要结局
Change from Baseline in Vulvovaginal Symptom Questionnaire
时间窗: Baseline, 1 , 2 , 3, 5, 8, and 14 months
Vulvovaginal Symptom Questionnaire will be used to evaluate improvement of vulvovaginal atrophy symptoms.
次要结局
- Number of participants with adverse events(throughout study duration, day 0 up to 17 months)
- Visual analog score for pain(day 0, 4 weeks, 8 weeks)
- Vaginal Health Index Improvement(Baseline, 1 , 2 , 3, 5, 8, and 14 months)
- Change from Baseline in Female Sex Function Index(Baseline, 1 , 2 , 3, 5, 8, and 14 months)
- Satisfaction questionnaire(2 weeks and 1 , 2 , 3, 5, 8, and 14 months)
研究者
研究点 (7)
Loading locations...
相似试验
撤回
2 期
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal AtrophyAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Breast AdenocarcinomaEstrogen Receptor PositiveProgesterone Receptor PositivePrognostic Stage 0 Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8DyspareuniaPrognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Vaginal DrynessVaginal ItchingVulvovaginal AtrophyNCT03666819Mayo Clinic
撤回
不适用
MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN StudyBreast Cancer FemaleGenitourinary Syndrome of MenopauseNCT04606550Mount Sinai Hospital, Canada
尚未招募
不适用
Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex ChronicusLichen Simplex ChronicusNCT06267066Cairo University60
Unknown
不适用
Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen SclerosusVulva Lichen SclerosusNCT05228483Xijing Hospital134
已完成
不适用
Use of Fractional CO2 Laser for the Treatment of Vulvovaginal Atrophy: a Double-blinded Randomized Placebo-controlled Clinical Trial.Vulvovaginal AtrophyNCT04021966prof. dr. Jan Deprest60